Pear Therapeutics, Inc. (“Pear Therapeutics”), the leader in developing and commercializing software-based medicines, called prescription…
Arboretum_JDDecember 6, 2021
Pear Therapeutics, Inc. today announced formulary availability of its commercial products at OptumRx, Inc., the…
Arboretum_JDAugust 10, 2021
Pear Therapeutics, Inc., today announced publication of a new analysis demonstrating the real-world cost impact…
Arboretum_JDJuly 28, 2021
Pear Therapeutics, Inc. (“Pear”), the leader in developing and commercializing prescription digital therapeutics (PDTs) to…
Arboretum_JDJune 22, 2021
Pear Therapeutics, Inc., recently announced the second closing of its Series D financing. The second…
Arboretum_JDMarch 3, 2021
Pear Therapeutics, Inc., (“Pear” or the “Company”) today announced that it has successfully closed an…
Arboretum_JDDecember 8, 2020
Pear Therapeutics, Inc., recently announced the availability of Somryst™, the first prescription digital therapeutic (PDT)…
Arboretum_JDNovember 17, 2020
Pear Therapeutics, Inc. recently announced that the Galien Foundation has awarded the 2020 Prix Galien…
Arboretum_JDNovember 2, 2020
Pear Therapeutics, Inc. recently announced the first participant enrolled in an open-label, decentralized clinical trial…
Arboretum_JDJuly 13, 2020
